Full coverage· Health· Updated
FDA-Cleared Home Ultrasound Device Paves Plasanmor’s Entry Into the U.S. Market
Plasanmor said it signed a U.S. partnership with Ouma Health to use its FDA-cleared home ultrasound device in pregnancy care across all 50 states. The announcement sent the Israeli company’s shares up 225.4% and lifted its market value to 214.5 million shekels.
2 newsrooms · 1 language · since
Plus
What happened
- 01Plasanmor partnered with Ouma Health to add its home ultrasound to pregnancy care.
- 02Ouma operates in all 50 U.S. states through insurers and health-system partnerships.
- 03The device received FDA clearance in November and targets obstetric care deserts.
- 04Plasanmor shares jumped 225.4% to a 214.5 million shekel market value.
- 05GE remains a nonexclusive distributor until June 2029 after a settlement.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- CentreNone
- RightNone
- HarediNone
- ArabNone
- Other2
How it broke
See which of the 2 newsrooms broke it, and who waited